ZEISS Looks Back on Overall Good Fiscal Year 2019/20 

Revenue reaches 6.3 billion euros (-2% vs. prior year) – EBIT at 922 million euros (-141 million euros vs. prior year) 

OBERKOCHEN, Germany, Dec. 17, 2020 /PRNewswire/ — Overall, the ZEISS Group had a good fiscal year 2019/20 (end of reporting period: 30 September 2020): revenue totaled 6.297 billion euros (prior year: 6.428 billion euros). With a slight decline of 2% due to the COVID-19 pandemic, revenue almost reached last year’s level. Around 90% of revenue was generated in markets outside Germany. Earnings before interest and taxes (EBIT) were also relatively high, reaching 922 million euros (prior year: 1.063 billion euros). The EBIT margin was 15%. Incoming orders increased to 6.814 billion euros (prior year: 6.575 billion euros).  

“On the whole, we were able to achieve a good business result for the ZEISS Group, thanks also to our broad portfolio and global positioning. We consider this an exceptional achievement by our employees – in unusual times,” says Dr. Karl Lamprecht, President and CEO of ZEISS. “Our global crisis management, supported by resilience measures that had already been developed, helped us tackle the challenges of the COVID-19 pandemic as well as possible.” 

 

* Not identical to Carl Zeiss Meditec Group 

Contact:Jörg NitschkePhone: +49 7364 20-3242joerg.nitschke@zeiss.comhttps://www.zeiss.com/ 

Photo: https://mma.prnewswire.com/media/1387366/dr_karl_lamprecht.jpg 

  

 

Leggi anche...
Le Fonti - New Pharma Italy TV
I più recenti
La casa farmaceutica indiana Piramal Pharma Limited registra una forte crescita
Settimana europea della salute mentale: i giovani sono a rischio
Teva Pharma, successo dei ricavi nel primo trimestre
Pancia gonfia: ecco i migliori rimedi naturali

Newsletter

Iscriviti ora per rimanere aggiornato su tutti i temi inerenti la salute.